|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Bacterial Infections | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Communicable Diseases | |||||
| Infection | |||||
| 3 | Interventions listed in this trial | ||||
| vancomycin plus aztreonam | |||||
| Ceftaroline | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Aztreonam | |||||
| Vancomycin | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Bacterial Agents | |||||
| Anti-Infective Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Cerexa, Inc. | |||||